


Is there a relationship between saccadic eye movements and cognitive function in multiple sclerosis?

J.A. Nij Bijvank^{1,2}, A. Eijlers³, L.J. Balk², H.S. Tan¹, B.M.J Uitdehaag², A. Petzold^{1,2,4}, L.J. van Rijn¹

E-mail: j.nijbijvank@vumc.nl

¹Department of ophthalmology, VU University Medical Center, Amsterdam, The Netherlands ²Neurology, Amsterdam neuroscience, VUmc MS Center Amsterdam, The Netherlands ³Anatomy & Neurosciences, Amsterdam neuroscience, VU University Medical Center, Amsterdam, The Netherlands ⁴Moorfields Eye Hospital, London, United Kingdom



Conclusion

- Cognitive function is related to peak velocity and gain in pro-saccade and anti-saccade tasks
- Consider precise quantitative saccadic testing as a potential surrogate outcome for cognitive function in longitudinal studies and treatment trials

References

- Downey DL, Stahl JS, Bhidayasiri R, et al. Saccadic and vestibular abnormalities in multiple sclerosis: sensitive clinical signs of brainstem and cerebellar involvement. *Ann N Y Acad Sci*, 2002; 956:438-40.
- Serra A, Derwenskus J, Downey DL, Leigh RJ. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. *J. Neurol.* 2003; 250:569-575.
- Muri RM, Meienberg O. The clinical spectrum of internuclear ophthalmoplegia in multiple sclerosis. *Arch. Neurol.* 1985; 42(9):851-855.
- Tsuda H, Ishikawa H, Matsunaga H, Mizutani T. [A neuroophthalmological analysis in 80 cases of multiple sclerosis]. *Rinsho Shinkeigaku*. 2004; 44:513-521.
- Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction. *Neurol.* 1991; 41:685-691.
- Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. *J. Neurol. Sci.* 2006; 245:41-46

Disclosures (none related to this work)
JANB, AE, HST, LJR: no disclosures - LJB: The VUmc MS Centre received research support from TEVA - BMJU: has received consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva - AP: member of the steering committee for the OCTIMS study (Novartis), no consulting fees. Performs OCT QC for the Passos study (Novartis), receives consulting fees.

